Latest from Columbia University Medical Center

Dawn L. Hershman, MD, MS, discusses current treatment considerations in premenopausal women with early-stage, hormone receptor-positive breast cancer.
Dawn Hershman, MD, MS, professor of medicine and epidemiology, leader of the Breast Cancer Program of the Herbert Irving Comprehensive Cancer Center at Columbia University, discusses the use of endocrine therapy in premenopausal women with early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.
Kevin Kalinsky, MD, MS, highlights recent developments in triple-negative breast cancer, including the potential role of immunotherapy in the neoadjuvant setting.
OncLive interviewed experts at the State of the Science Summits™ in January 2020 on what they are going to work on improving in clinical practice this year.  
Kevin Kalinsky, MD, MS, discusses the clinical impact of the combination of atezolizumab and nab-paclitaxel in triple-negative breast cancer.
Gulam A. Manji, MD, PhD, discusses the importance of discovering other actionable targets for patients with colorectal cancer.
Gulam A. Manji, MD, PhD, discusses treatment for patients with colorectal cancer who harbor NTRK fusions.
Gulam A. Manji, MD, PhD, discusses the difference between right- and left-sided tumors in colorectal cancer and the appropriate treatment for right-sided tumors based on a subgroup analysis. 
Publication Bottom Border
Border Publication